CEO Krish Krishnan highlighted Krystal Biotech's strong position across commercial, clinical, and financial areas. He noted the successful global expansion of VYJUVEK, particularly with the upcoming ...

Drug developer Suma Krishnan was 51 when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder, called dystrophic epidermolysis bullosa, in which the skin becomes as ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in ...

Krish Krishnan, CEO, Cristal Biotech: And if there’s anything we could help between now and then, for example, we do you know, how they have EB clinics in The US. Mhmm. Maybe simulator creates such ...

Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a ...

On Wednesday, 14 May 2025, Krystal Biotech (NASDAQ:KRYS) presented at the BofA Securities 2025 Healthcare Conference, providing a comprehensive overview of its strategic positioning. The company ...